4Ingersoll GL, Wasilewski A, Hailer M, et al. Efect of concord grape juiee on chemotherapy - induced nausea and vomiting:results of a pi- lot study[J]. Oncol Nurs Forum,2010,37 (2) :213.
2Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: Reliability,validity, and guidelines[J]. J Clin Oncology,1984, 2(3):187-193.
3U.S. national cancer institute.Ctep,nci guidelines: adverse event reporting requirements[R]. Effective:cancer therapy evaluation program, 2005.
4Hesketh PJ. Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting [J]. Cancer Invest, 2000, 18(2): 163-173.
5Eisenberg P, MacKintosh FR, Ritch P, et al. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy:a dose-ranging clinical study [J]. Ann Oncol, 2004,15(2):330-337.
6Aapro MS, Grunberg SM, Manikhas GM, et al. A phase In, doubleblind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy[J]. Ann 0ncol,2006,17(9):1441- 1449.
7Maemondo M, Masuda N, Sekine I, et al. A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy[J]. Ann Oncol, 2009, 20( 11 ): 1860-1866.
8Lorusso V, Spedicato A, Petrucelli L, et al. Single dose of palonosetron plus dexamethasone to control nausea, vomiting and to warrant an adequate food intake in patients treated with highly emetogenic chemotherapy ( HEC ) [J]. Support Care Cancer,2009,17 (12): 1469-1473.
9Rojas C, Stathis M, Alt J, et al. Additional binding mechanism of. palonosetron to the 5-HT3 receptor versus first generation 5-HT3 receptor antagonists[J]. J Clin Oncol, 2007, 25 ( 18S ):713.
